Table 1. Baseline Characteristics of Matched Pregnancy Cohorts on Propensity Scores for Analyses of Major Malformations.
| Characteristic | Oral Terbinafine vs Unexposed, No. (%) | Topical Terbinafine vs Unexposed, No. (%) | Oral vs Topical Terbinafine Exposed, No. (%) | |||
|---|---|---|---|---|---|---|
| Oral Terbinafine (n = 522) | Unexposed (n = 5220) | Topical Terbinafine (n = 1476) | Unexposed (n = 14 760) | Oral Terbinafine (n = 510) | Topical Terbinafine (n = 510) | |
| Age at pregnancy onset, y | ||||||
| ≤19 | 7 (1.3) | 104 (2.0) | 23 (1.6) | 273 (1.8) | 7 (1.4) | 5 (1.0) |
| 20-24 | 50 (9.6) | 497 (9.5) | 215 (14.6) | 2188 (14.8) | 50 (9.8) | 54 (10.6) |
| 25-29 | 162 (31.0) | 1591 (30.5) | 506 (34.3) | 5143 (34.8) | 157 (30.8) | 160 (31.4) |
| 30-34 | 201 (38.5) | 2094 (40.1) | 503 (34.1) | 5107 (34.6) | 198 (38.8) | 199 (39.0) |
| ≥35 | 102 (19.5) | 934 (17.9) | 229 (15.5) | 2049 (13.9) | 98 (19.2) | 92 (18.0) |
| Married or living with partner | 445 (85.2) | 4482 (85.9) | 1283 (86.9) | 12 738 (86.3) | 437 (85.7) | 432 (84.7) |
| Place of birth | ||||||
| Denmark | 423 (81.0) | 4285 (82.1) | 1256 (85.1) | 12 766 (86.5) | 417 (81.8) | 424 (83.1) |
| Europe | 32 (6.1) | 246 (4.7) | 76 (5.1) | 704 (4.8) | 31 (6.1) | 29 (5.7) |
| Outside of Europe | 67 (12.8) | 689 (13.2) | 144 (9.8) | 1290 (8.7) | 62 (12.2) | 57 (11.2) |
| Region of residence | ||||||
| Capital Denmark | 149 (28.5) | 1544 (29.6) | 432 (29.3) | 4300 (29.1) | 144 (28.2) | 150 (29.4) |
| Zealand Denmark | 58 (11.1) | 563 (10.8) | 205 (13.9) | 2092 (14.2) | 58 (11.4) | 54 (10.6) |
| Southern Denmark | 109 (20.9) | 1103 (21.1) | 293 (19.9) | 2900 (19.6) | 109 (21.4) | 105 (20.6) |
| Central Denmark | 149 (28.5) | 1488 (28.5) | 387 (26.2) | 3886 (26.3) | 144 (28.2) | 145 (28.4) |
| North Denmark | 57 (10.9) | 522 (10.0) | 159 (10.8) | 1582 (10.7) | 55 (10.8) | 56 (11.0) |
| Gross household income, quartile | ||||||
| 1 | 129 (24.7) | 1236 (23.7) | 405 (27.4) | 4083 (27.7) | 118 (23.1) | 133 (26.1) |
| 2 | 124 (23.8) | 1176 (22.5) | 448 (30.4) | 4352 (29.5) | 113 (22.2) | 107 (21.0) |
| 3 | 134 (25.7) | 1401 (26.8) | 376 (25.5) | 3835 (26.0) | 114 (22.4) | 106 (20.8) |
| 4 | 135 (25.9) | 1407 (27.0) | 247 (16.7) | 2490 (16.9) | 165 (32.4) | 164 (32.2) |
| Educational level, y | ||||||
| <12 | 124 (23.8) | 1266 (24.3) | 383 (25.9) | 3937 (26.7) | 122 (23.9) | 129 (25.3) |
| 12-13 | 93 (17.8) | 956 (18.3) | 232 (15.7) | 2249 (15.2) | 90 (17.6) | 88 (17.3) |
| 14-15 | 132 (25.3) | 1290 (24.7) | 402 (27.2) | 4010 (27.2) | 128 (25.1) | 128 (25.1) |
| >15 | 173 (33.1) | 1708 (32.7) | 459 (31.1) | 4564 (30.9) | 170 (33.3) | 165 (32.4) |
| Year of pregnancy onset | ||||||
| 1997-2000 | 69 (13.2) | 724 (13.9) | 523 (35.4) | 5322 (36.1) | 69 (13.5) | 72 (14.1) |
| 2001-2004 | 104 (19.9) | 1051 (20.1) | 352 (23.8) | 3501 (23.7) | 104 (20.4) | 99 (19.4) |
| 2005-2008 | 134 (25.7) | 1425 (27.3) | 268 (18.2) | 2616 (17.7) | 131 (25.7) | 139 (27.3) |
| 2009-2012 | 122 (23.4) | 1227 (23.5) | 194 (13.1) | 1977 (13.4) | 118 (23.1) | 112 (22.0) |
| 2013-2016 | 93 (17.8) | 793 (15.2) | 139 (9.4) | 1344 (9.1) | 88 (17.3) | 88 (17.3) |
| Parity | ||||||
| 1 | 228 (43.7) | 2341 (44.8) | 699 (47.4) | 7144 (48.4) | 225 (44.1) | 225 (44.1) |
| 2 | 177 (33.9) | 1672 (32.0) | 529 (35.8) | 5289 (35.8) | 174 (34.1) | 181 (35.5) |
| ≥3 | 117 (22.4) | 1207 (23.1) | 248 (16.8) | 2327 (15.8) | 111 (21.8) | 104 (20.4) |
| Multiple-birth pregnancy | 11 (2.1) | 123 (2.4) | 33 (2.2) | 305 (2.1) | 11 (2.2) | 12 (2.4) |
| Smoking during pregnancy | 82 (15.7) | 813 (15.6) | 272 (18.4) | 2612 (17.7) | 80 (15.7) | 83 (16.3) |
| Previous pregnancy with major malformations outcome | 13 (2.5) | 121 (2.3) | 16 (1.1) | 143 (1.0) | 10 (2.0) | 10 (2.0) |
| Antidiabetic drugs used in past year | 5 (1.0) | 29 (0.6) | 21 (1.4) | 161 (1.1) | 5 (1.0) | 6 (1.2) |
| Drugs used for IVF in past 3 mo | 16 (3.1) | 176 (3.4) | 87 (5.9) | 781 (5.3) | 16 (3.1) | 15 (2.9) |
| No. of drugs used in past year | ||||||
| 1-2 | 170 (32.6) | 1733 (33.2) | 487 (33.0) | 4876 (33.0) | 159 (31.2) | 170 (33.3) |
| 3-4 | 133 (25.5) | 1250 (23.9) | 400 (27.1) | 4167 (28.2) | 135 (26.5) | 134 (26.3) |
| ≥5 | 173 (33.1) | 1780 (34.1) | 381 (25.8) | 3653 (24.7) | 174 (34.1) | 176 (34.5) |
| No. of hospitalizations in past year | ||||||
| 1 | 74 (14.2) | 634 (12.1) | 226 (15.3) | 2046 (13.9) | 74 (14.5) | 65 (12.7) |
| 2 | 9 (1.7) | 95 (1.8) | 27 (1.8) | 199 (1.3) | 9 (1.8) | 11 (2.2) |
| ≥3 | 5 (1.0) | 35 (0.7) | 15 (1.0) | 129 (0.9) | 5 (1.0) | 5 (1.0) |
| No. of outpatient contacts in past year | ||||||
| 1 | 82 (15.7) | 704 (13.5) | 207 (14.0) | 2100 (14.2) | 79 (15.5) | 73 (14.3) |
| 2 | 27 (5.2) | 258 (4.9) | 84 (5.7) | 681 (4.6) | 27 (5.3) | 21 (4.1) |
| ≥3 | 11 (2.1) | 96 (1.8) | 36 (2.4) | 284 (1.9) | 11 (2.2) | 12 (2.4) |
Abbreviation: IVF, in vitro fertilization.